SCHEMBL5033954

SCHEMBL5033954

COc1ccc(-c2ccc(F)cc2)c2oc(N)nc12

nearest known ligand 0.45

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
RPS6KA2 Q15349 1/20 0.45
ABL1 P00519 2/20 0.40
NTRK1 P04629 2/20 0.40
RET P07949 2/20 0.40
MET P08581 2/20 0.40
FLT3 P36888 2/20 0.40
RPS6KA3 P51812 2/20 0.40
LIMK1 P53667 2/20 0.40
MAP4K2 Q12851 2/20 0.40
NTRK2 Q16620 2/20 0.40
CLK4 Q9HAZ1 2/20 0.40
CHEK1 O14757 1/20 0.40
DAPK3 O43293 1/20 0.40
JAK2 O60674 1/20 0.40
PIM1 P11309 1/20 0.40
MAP2K2 P36507 1/20 0.40
MAPK8 P45983 1/20 0.40
GSK3A P49840 1/20 0.40
GSK3B P49841 1/20 0.40
TYRO3 Q06418 1/20 0.40

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL5036141 0.86 NUDT1 (0.47) RPS6KA2ABL1NTRK1RETMET
SCHEMBL5036203 0.76 ALDH1A1 (0.41) ABL1NTRK1RETMETFLT3
SCHEMBL5040888 0.76 RPS6KA2 (0.40) RPS6KA2NPC1RAB9AHPGDKDM4E
SCHEMBL5037699 0.74 ADCY1 (0.51) NPC1CYP1A2POLBHPGDKDM4E
SCHEMBL5131523 0.74 HTT (0.43) ABL1NTRK1RETMETFLT3
SCHEMBL5037775 0.73 ALDH1A1 (0.45) ABL1POLBMEN1ALDH1A1MAPT
SCHEMBL22634327 0.72 P2RX3 (0.44) ABL1NTRK1RETMETFLT3
SCHEMBL5036142 0.70 KMT2A (0.46) NPC1POLBHPGDKDM4EMEN1
SCHEMBL5036500 0.70 HTT (0.54) RAB9ACYP1A2POLBHPGDKDM4E
SCHEMBL29043501 0.67 PDE4D (0.47) CYP1A1CYP1B1NPC1RAB9ACYP1A2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-1587799-B1 BENZOXAZOLE DERIVATIVES AND THEIR USE AS ADENOSINE RECEPTOR LIGANDS HOFFMANN LA ROCHE (CH) 2008-03-12 EP disclosed
US-6992083-B2 deiodination/arylation, acylation or hydrogenation of a substituted 4-methoxy-bezoxazole derivative; adenosine receptor ligands; Parkinson's and Alzheimer's Diseases; 2-Chloromethyl-N-[7-(4-fluoro-phenyl)-4-methoxy-benzooxazol-2-yl]-isonicotinamide HOFFMAN-LA ROCHE INC. (US) 2006-01-31 US disclosed
EP-1587799-A1 BENZOXAZOLE DERIVATIVES AND THEIR USE AS ADENOSINE RECEPTOR LIGANDS F. HOFFMANN-LA ROCHE AG (CH) 2005-10-26 EP disclosed
US-20040152702-A1 Benzoxazol derivatives F. HOFFMANN-LA ROCHE AG (CH) 2004-08-05 US disclosed
WO-2004063177-A1 BENZOXAZOLE DERIVATIVES AND THEIR USE AS ADENOSINE RECEPTOR LIGANDS F. HOFFMANN-LA ROCHE AG (CH) 2004-07-29 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20040152702-A1 Benzoxazol derivatives P2RX3, P2RX2, P2RX1 RPS6KA2 1124/4885ABL1 603/4885NTRK1 563/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.